ALN-Immunomodulatory Agents

About Alnair Therapeutics

Alnair Therapeutics is a private, preclinical-stage biotech founded in 2020, pioneering a novel drug delivery platform that targets lactate, a universal metabolite of the Warburg Effect in tumors. Its core technology, the Alnair Lactate-reactive Nanoparticle (ALN), uses a self-immolative cap to release encapsulated drugs specifically in the high-lactate tumor microenvironment, aiming to reduce systemic toxicity and enable dose intensification. The lead program focuses on repurposing cytotoxic chemotherapy for breast, ovarian, and sarcoma cancers, with a pipeline exploring targeted small molecules and immunomodulatory agents. The company is headquartered in Cambridge, Massachusetts, with an additional office in Chicago, Illinois.

Therapeutic Areas